Cancer does not yield to a single discovery, a single company, or a single funding cycle. It is a generational problem — and almost everything aimed at it is structured for the opposite.
One problem. Both ends. The full arc.
Most of the money aimed at cancer is organized for the wrong timescale. Short horizons, defined exits, returns measured in a handful of years rather than the decades the problem actually asks for. The result is a field that is brilliant in its parts and incoherent as a whole — remarkable science pursued inside structures that cannot afford to wait for it.
BioFund was built as a different structure. It began not with a business plan but with a sentence. In 2018, a scientist said, plainly: "I will cure cancer." The reasonable response to that sentence is skepticism. The honest response is to ask what it would actually take — and then to build the thing that makes the work possible and protects it from everything that usually kills it: impatience, the need to sell, the pressure to narrow a mission down to whatever can be exited fastest.
Cancer is one problem wearing different coats. The wall between its disciplines, its species, its timescales — these are accidents of how the field grew up, not facts of how the disease works.
BioFund's approach is holistic in a precise sense — not doing everything, but refusing three separations that conventional approaches treat as natural, and that we believe are the reason the conventional approaches stall.
Almost all of oncology is organized around treating people who are already sick. That work is essential and we are deeply in it. But the largest gains against cancer over a lifetime come earlier — from reducing the burden the body carries before disease takes hold. Prevention is unglamorous, slow to prove, and nearly impossible to fund in a normal model because no one exits a healthy population. That is precisely why it belongs to us.
Cancer is not a uniquely human affliction. Dogs and other companion animals develop cancers spontaneously, with biology that often resembles our own far more faithfully than an engineered mouse ever will. Treating their disease is not a detour on the way to human medicine. It is care for those animals in its own right — and at the same time, the fastest and most honest path to therapies that will one day reach people. → OneHealth
In the standard arrangement, money and purpose are in tension — the investor's clock works against the scientist's. BioFund is built so the two pull in the same direction. The capital is structured to want what the mission wants: time. → No Exit.
A mission this long needs durable machinery underneath it — not a string of products, but platforms that keep producing. BioFund runs on two.
The capability to design, build, and produce the biological tools that modern oncology depends on — engineered cell lines, biologic proteins, biosimilars, and therapeutics aimed first at companion-animal cancers. Built for our own research. Opened selectively to mission-aligned partners.
Ultra-fine particle processing of natural bioactive compounds — raising bioavailability so the body can actually use what it takes in. Expressed through RAFFINÉ in the culinary world and PURE° in functional wellness. Targeted prevention, made real.
One engine works on the disease. The other works on the conditions that precede it. Together they cover the whole arc — which is the point.
A mission that depends on perpetual generosity is fragile. Generosity tires; circumstances change; the work outlives the goodwill that started it. So the economics are designed to sustain themselves.
Mission capital funds the platforms. The platforms give rise to commercial activities — culinary and wellness brands built on UFP500°, the licensing of biological tools, companion-animal therapeutics — and those activities generate revenue that refuels the mission. Over time, the cure and prevention work is meant to be carried less and less by fresh capital and more and more by the value the platforms themselves create.
Mission capital funds platforms. Platforms give rise to commerce. Commerce refuels the mission. → The Flywheel
None of this works without the right structure. That structure is what these papers exist to explain — and, we hope, to spread.
BioFund is backed by seven families and built to be permanent and anti-exit. There is no liquidation event on the horizon distorting every decision behind it, no clock counting down to a forced sale. That single design choice changes what becomes possible. It lets us pursue prevention, which has no exit. It lets us run OneHealth properly, in the right sequence, rather than rushing to whatever can be monetized first. It lets us build platforms as decade-long assets rather than props for the next round. → No Exit.
Research Programmes run on a 7-year horizon — three generations of seven, a 21-year arc that matches the actual timescale on which cancer biology yields answers. The Development engine runs on three-year cycles, with defined deliverables and go/no-go decisions. Two different clocks, each at the speed the work actually requires. → Two Clocks
This is what we mean by legacy — not a word on a wall, but a structural fact. The organization is meant to outlast its founders and to be judged on a timescale that matches the disease, not the market.
The mission is too large for any single group, and we have never pretended otherwise. The work runs through partnerships — in animal health, in academic oncology, in the bioeconomy that supplies and sustains the prevention platform. We bring capital that can wait, platforms that produce, and a structure that lets collaborators do their best work without being absorbed or rushed. What we ask in return is alignment of purpose.
No one can do this alone. That is not a slogan. It is the reason every partnership BioFund enters is built the way it is — long-term, mission-first, and structured so the science leads the relationship rather than the other way around.
We treat cancer as one problem across species, work both ends of it — prevention and cure — and have built the kind of organization that can stay in the fight for as long as the fight takes. Most of the field is structurally unable to wait. We are built to.
Part of the BioFund Concept Paper series. ← Foundations · OneHealth →